Solid Biosciences Inc. (SLDB)
SLDB Stock Price Chart
Explore Solid Biosciences Inc. interactive price chart. Choose custom timeframes to analyze SLDB price movements and trends.
SLDB Company Profile
Discover essential business fundamentals and corporate details for Solid Biosciences Inc. (SLDB) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
26 Jan 2018
Employees
100.00
Website
https://www.solidbio.comCEO
Alexander G. Cumbo
Description
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
SLDB Financial Timeline
Browse a chronological timeline of Solid Biosciences Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 13 May 2026
Upcoming earnings on 5 Nov 2025
EPS estimate is -$0.42.
Earnings released on 12 Aug 2025
EPS came in at -$0.42 surpassing the estimated -$0.51 by +17.65%.
Earnings released on 15 May 2025
EPS came in at -$0.59 falling short of the estimated -$0.53 by -11.32%.
Earnings released on 6 Mar 2025
EPS came in at -$0.89 falling short of the estimated -$0.79 by -12.66%.
Earnings released on 6 Nov 2024
EPS came in at -$0.79 falling short of the estimated -$0.67 by -17.91%.
Earnings released on 13 Aug 2024
EPS came in at -$0.61 surpassing the estimated -$0.68 by +10.29%.
Earnings released on 15 May 2024
EPS came in at -$0.64 falling short of the estimated -$0.57 by -12.28%.
Earnings released on 13 Mar 2024
EPS came in at -$1.00 surpassing the estimated -$1.01 by +0.99%, while revenue for the quarter reached $4.74M .
Earnings released on 8 Nov 2023
EPS came in at -$1.05 surpassing the estimated -$1.20 by +12.50%.
Earnings released on 14 Aug 2023
EPS came in at -$1.25 surpassing the estimated -$1.52 by +17.76%.
Earnings released on 11 May 2023
EPS came in at -$1.54 surpassing the estimated -$1.83 by +15.85%.
Earnings released on 23 Mar 2023
EPS came in at -$0.68 surpassing the estimated -$2.70 by +74.81%, while revenue for the quarter reached $8.09M , beating expectations by +591.79%.
Earnings released on 10 Nov 2022
EPS came in at -$2.71 falling short of the estimated -$2.59 by -4.63%.
Stock split effective on 28 Oct 2022
Shares were split 1 : 15 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 11 Aug 2022
EPS came in at -$3.30 falling short of the estimated -$3.15 by -4.76%, while revenue for the quarter reached $6.17M , beating expectations by +51.03%.
Earnings released on 27 Apr 2022
EPS came in at -$3.30 falling short of the estimated -$2.70 by -22.22%, while revenue for the quarter reached $1.93M , missing expectations by -28.12%.
Earnings released on 14 Mar 2022
EPS came in at -$2.55 surpassing the estimated -$3.00 by +15.00%, while revenue for the quarter reached $3.15M , beating expectations by +82.08%.
Earnings released on 3 Nov 2021
EPS came in at -$2.40 surpassing the estimated -$2.85 by +15.79%, while revenue for the quarter reached $3.54M , beating expectations by +167.95%.
Earnings released on 16 Aug 2021
EPS came in at -$2.55 surpassing the estimated -$2.70 by +5.56%, while revenue for the quarter reached $3.59M , beating expectations by +172.27%.
Earnings released on 14 May 2021
EPS came in at -$2.85 surpassing the estimated -$4.20 by +32.14%, while revenue for the quarter reached $3.34M , missing expectations by -20.99%.
Earnings released on 15 Mar 2021
EPS came in at -$4.65 surpassing the estimated -$5.10 by +8.82%, while revenue for the quarter reached $98.32M .
Earnings released on 5 Nov 2020
EPS came in at -$6.60 falling short of the estimated -$4.80 by -37.50%.
SLDB Stock Performance
Access detailed SLDB performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.